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A variety of transcription factors includingWilms tumor gene
(Wt-1), steroidogenic factor 1 (Sf-1), dosage-sensitive sex re-
versal, adrenal hypoplasia congenita on the X-chromosome,
Gene 1 (Dax-1), and pre-B-cell transcription factor 1 (Pbx1)
have been defined as necessary for regular adrenocortical
development. However, the role of Pbx1 for adrenal growth
and function in the adult organism together with the molec-
ular relationship between Pbx1 and these other transcription
factors havenot been characterized.Wedemonstrate thatPbx
haploinsufficiency (Pbx1/) in mice is accompanied by a sig-
nificant lower adrenalweight in adult animals comparedwith
wild-type controls. Accordingly, baseline proliferating cell
nuclear antigen levels are lower in Pbx1/ mice, and unilat-
eral adrenalectomy results in impaired contralateral compen-
satory adrenal growth, indicating a lower proliferative po-
tential in the context of Pbx1 haploinsufficiency. In
accordance with the key role of IGFs in adrenocortical pro-
liferation and development, real-time RT-PCR demonstrates
significant lower expression levels of the IGF-I receptor, and
up-regulation of IGF binding protein-2. Functionally, Pbx1/
mice display a blunted corticosterone response after ACTH
stimulation coincident with lower adrenal expression of the
ACTH receptor (melanocortin 2 receptor, Mc2-r). Mechanis-
tically, in vitro studies reveal that Pbx1 and Sf-1 synergisti-
cally stimulates Mc2-r promoter activity. Moreover, Sf-1 di-
rectly activates thePbx1promoteractivity in vitroand in vivo.
Taken together, these studies provide evidence for a role of
Pbx1 in the maintenance of a functional adrenal cortex me-
diated by synergistic actions of Pbx1 and Sf-1 in the tran-
scriptional regulationof the critical effector of adrenocortical
differentiation, the ACTH receptor. (Endocrinology 148:
693–704, 2007)
THE TRANSCRIPTION FACTOR Pbx1 (pre-B-cell tran-scription factor 1) belongs to the group of non-Hox-
homeodomain transcription factors that significantly con-
tribute to embryonic differentiation and organogenesis.
During this process, Pbx1 allows homeodomain proteins
such as Hox (1), engrailed (2), MyoD (3), Meis (4), or Pdx (5)
to bind to DNA with higher affinity and specificity. Com-
plexes of Pbx1/Hox can act as transcriptional activators or as
repressors depending on the recruitment of other transcrip-
tion factors and modulation through extracellular signals.
Moreover,Meis and Prep proteins regulate Hox activity both
as components of the DNA-bound Hox complex and by
regulating Pbx activity in the absence of DNA (6). In addi-
tion, recent evidence suggests that Pbx1/Meis dimers pen-
etrate repressive chromatin enabling consecutive binding of
cofactors such as Hox or MyoD that in turn results in gene
activation or its repression (3). The physiological importance
of Pbx1 during development is strongly supported by the
intrauterine death of Pbx1/ mice at embryonic d 15–16
with severe perturbation in organ development (7). These
pleiotropic defects associated with Pbx1 deficiency concerns
hematopoiesis in the fetal liver (7), pancreas development (8),
nephrogenesis (9), and skeleton development (10). As ex-
pected from the functional interaction between Pbx1 and
Hox proteins, these developmental abnormalities to a great
extent overlap phenotypes found in different Hox null mu-
tant mice (11–13).
The significance of Pbx1 for steroidogenesis has been es-
tablished by earlier studies on Pbx1-dependent expression of
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17-hydroxylase/17,20-lyase (Cyp17) (14). Cyp17 is required
for cortisol and androgen biosynthesis and therefore plays a
key role in biological processes including sexual differenti-
ation. Overexpression of Pbx1 has been demonstrated to
enhance the cAMP evoked transcriptional response in an in
vitro model, thus indicating a modulation of cAMP-depen-
dent transcription through Pbx1. Additional evidence for
Pbx1-dependent effects on adrenal function comes from the
phenotypical description of significant adrenal and urogen-
ital differentiation defects including severe adrenal hypopla-
sia (15) in Pbx1/ animals associated with minimal expres-
sion of steroidogenic factor 1 (Sf-1), an important regulator
of adrenocortical cell commitment and steroidogenesis. In
accordance with this observation, only recently, Pbx1-
dependent initiation of Sf-1 expression during murine ad-
renal development has been demonstrated in a series of
transgenic approaches in vivo (16).
Taken together, Pbx1 has been implicated as an additional
key factor for adrenocortical organogenesis and growth.
However, the lethal phenotype of Pbx1/ animals has pre-
cluded the elucidation of possible Pbx1-dependent effects on
adrenal function in the adult organism. Therefore, we used
a viable, haploinsufficient mouse model lacking the critical
domain for Pbx1-DNA interaction to further define the con-
tribution of Pbx1 for adrenal growth and steroidogenesis.
Materials and Methods
Generation of Pbx1 haploinsufficient animals
The Pbx1flox1 targeting vector was constructed by cloning of three
adjacent Pbx1 genomic fragments into a pflox plasmid (17) (Fig. 1A). The
targeted sequence (referred to as target) was composed of Pbx1 exon 6
(corresponding to 1192–1356 bp in PBX1a mRNA, accession no.
AF020196) flanked by 700-bp upstream and 280-bp downstream intronic
sequences (Fig. 1A). In the course of Pbx1flox1 vector preparation, a
HindIII restriction digest site was removed from the genomic sequence
upstream of the targeted exon 6 (Fig. 1A). Removal of this restriction site
by enzymatic digest and Klenow polymerase fill-in reaction allowed for
Southern detection of homologous recombination events with the ex-
ternal Southern probe located upstream of the vector sequences (Fig. 1,
A and B).
The NotI linearized Pbx1flox1 plasmid was electroporated into the
embryonic d 14 embryonic stem (ES) cells followed by 6 d of G418
selection. After positive selection with G418, homologous recombinant
cloneswere identified by Southern blot analysis usingHindIII digest and
the 5 external Southern blot probe. This probe hybridized to the 8-kb
fragment of the wild-type allele and the 16-kb fragment of a correctly
targeted allele (Fig. 1B). The homologous recombination events, detected
by Southern blot, were confirmed by PCR amplification of the 5 and 3
ends of the targeting vector, with one primer based on the sequence
inside and one external to the vector sequence (Fig. 1C). Cells were
electroporated with 20 g CMV-Cre plasmid (kindly provided by Dr.
Florian Otto) and serially diluted before plating. Colonies were picked
and PCR analyzed for the loss of target and selection cassette sequences
(data not shown). Four clones of ES cells heterozygous for the Pbx1
knockout were microinjected into blastocysts of C57BL/6 background.
A total of 57 microinjected blastocysts were retransferred into pseudo-
pregnant foster mice, and three highly chimeric males were born. One
of the male chimeras gave a germline transmission of the Pbx1 knockout
allele that was further bred onto the C57BL/6 background. Genotyping
was performed by genomic PCR of tail DNA using primers flanking the
targeted exon 6 yielding a 600-bp fragment for the knockout allele and
a 1.2-kb fragment for the wild-type allele. Because this long fragment
was not regularly amplified under the applied PCR conditions, 18s
primers resulting in a 151-bp fragment were used as a positive ampli-
fication control (Fig. 1D).
Timed pregnancies of Pbx1 heterozygote F2 generation mice were set
up andd-14.5 embryos obtained. Phenotypically Pbx1/ embryoswere
similar to Pbx1/ mice described previously (10). Among externally
visible knockout features, Pbx1/ pups were distinguished by sc
edema, diminished vascularization and consequent pallor, slender tho-
rax and abdomen, hunched posture, and abnormal orientation of both
fore and hind limbs (data not shown).
Animal experiments
All experiments involving animals were performed in accordance
with institutionally approved and current animal care guidelines. An-
imals were maintained under standard conditions of temperature (22 C)
and lighting (12 h light, 12 h dark) and with food and water given ad
libitum. Pbx1/ haploinsufficient andwild-typemice were obtained by
breeding Pbx1/mice with wild-type animals (C57BL/6; Jackson Lab-
oratory, Bar Harbor, ME). Generation of Sf-1/ haploinsufficient an-
imals has been described earlier (18).
For evaluation of adrenal morphology, expression studies and hor-
monal measurements, 10-wk-old female Pbx1/ mice and wild-type
controls were isolated and kept in a quiet environment overnight. Blood
samples for hormonal measurements (n  6 per genotype) were ob-
tained by retroorbital bleeding after isoflurane anesthesia for restrained
stress and ACTH-stimulated experiments and trunk blood collection for
baseline measurements. In all instances, blood collection was done
within 60 sec after initial mouse handling. Restrained stresswas induced
by placing the animals in a 50-ml Falcon tube for 30 min. ACTH stim-
ulationwas performed after injection of weight-adjusted doses of ACTH
and blood collection after 30 min as described earlier (19). After micro-
dissection, adrenals were measured and the tissues were snap frozen for
protein/RNA extraction and in situ hybridization or immersed in para-
formaldehyde for 3 h for histological analysis.
FIG. 1. Schematic representation of the Pbx1 locus and targeting
vector. A, Schematic representation of allele targeting by homologous
recombination and subsequent transient Cre recombinase expres-
sion. As a result of homologous recombination and subsequent Cre
expression, sequences containing exon 6 as well as the selection cas-
sette were removed, yielding neomycin (Neo)-sensitive Pbx1/ ES
cell clones. B, Southern blot analysis of HindIII-digested DNA from
Pbx1 clones after first homologous recombination before Cre treat-
ment indicated a shift of the wild-type (wt) 8-kb band to 16 kb due to
the loss of a HindIII site in the homology arm. C, Southern blot
analysis was confirmed by long-range PCR with primers within and
outside of the targeted sequence yielding 8- and 2-kb fragments of the
5 and 3 homology arms of the vector. D, Genotyping of wild-type
(/) and heterozygous Pbx1 knockout animals (/) was performed
by PCR (see text for details). B, BamHI; Bg, BglII; E, EcoRI; H,
HindIII; N, NotI; S, SalI.
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For compensatory adrenal growth experiments, 9-wk-old male
Pbx1/ or wild-type mice were subjected to left-sided adrenalectomy
(n 6 per genotype) on d 0 following standard procedures as described
earlier (20). Mice were euthanized on d 3, and the remaining adrenals
were collected. All adrenal weights were measured after careful
microdissection.
For real-time expression analysis of Pbx1, 8-wk-old female Sf-1/
animals and age-matchedwild-type controls (n 3 each)were usedwith
adrenals snap frozen after microdissection.
Adrenal morphology
Formorphological evaluation, tissueswere dehydrated, embedded in
paraffin, sectioned, and stained with hematoxylin and eosin following
standard procedures. Hematoxylin- and eosin-stained adrenal sections
from wild-type and Pbx1/mice were examined with a standard light
microscope using 400 magnification. Cell nuclei within the zona fas-
ciculata of three independent sections from three different animals per
group were counted under standardized conditions. Cell counts were
expressed as cell number per high-power field. Morphometric analysis
for quantification of the x-zone was performed on at least three indi-
vidual mice per genotype as described earlier (20).
Immunohistochemistry
For immunohistochemical analysis, paraffin-embedded sections
were rehydrated, blocked with 0.3% H2O2 in methanol for 10 min, and
incubated with blocking buffer for 15 min. Primary antibodies [prolif-
erating cell nuclear antigen (PCNA), 1:500 (Santa Cruz Biotechnology,
Santa Cruz, CA); SF-1, 1:500 (K. Morohashi); PBX1, 1:100 (Abcam, Cam-
bridge, UK); and 20-hydroxysteroid dehydrogenase (20HSD), 1:5000
(Y.Weinstein)]were incubated overnight at 4 C after dilution in blocking
buffer containing 3% BSA (Roche Diagnostics, Mannheim, Germany),
5% goat serum (Jackson ImmunoResearch Laboratories, West Grove,
PA), and 0.5% Tween 20. After rinsing for 15 min in PBS, secondary
antibody (goat antirabbit biotinylated IgG; Vector Laboratories, Burlin-
game, CA) was applied for 30 min at room temperature. Bound primary
antibody was detected using the Immunocruz Kit (Santa Cruz Biotech-
nology) according to the manufacturer’s protocol.
Western blot analysis
Adrenals were sonicated on ice until tissue was disrupted in RIPA
buffer (50 mm Tris, 150 mm sodium chloride, 1.0 mm EDTA, 1%
Nonidet P40, and 0.25% sodium deoxycolate, pH 7.0) that was sup-
plemented with complete protease inhibitor cocktail (Roche, Mann-
heim, Germany) and phosphatase inhibitor cocktail 1 (Sigma Chem-
ical Co., St. Louis, MO). After incubation by rotating at 4 C for 1 h,
followed by a centrifugation step at 10,000 g at 4 C for 5 min, protein
concentration was assessed using a protein assay (Bio-Rad, Munich,
Germany). Then, 10 g of the protein preparation was run on a 10%
acrylamide gel at 110 V for 1 h and transferred to nitrocellulose at 120
mA for 1 h. The nitrocellulose was then incubated with 5% nonfat dry
milk overnight at 4 C with either rabbit anti-PCNA antibody (Santa
Cruz Biotechnology) at a dilution of 1:1000, rabbit anti-SF-1 antibody
at 1:1500 (K. Morohashi), or chicken anti-IGF-I receptor antibody at
2 g/ml (Upstate, Charlottesville, VA), respectively. The washed
blots were then incubated with suitable secondary antibodies con-
jugated to horseradish peroxidase (sheep antimouse, donkey anti-
rabbit, or rabbit antichicken, all from Amersham Biosciences, Little
Chalfont, UK) at a dilution of 1:10,000 for 1 h at room temperature.
Antibody binding to the membrane was visualized using the KPL
Western Luminescence ECL plus (Amersham) chemiluminescent de-
tection system. All immunoblots were performed on at least six
different animals per genotype. Bands were quantified using volume
quantification (Quantity one, version 4.2.0; Bio-Rad, Hercules, CA),
and resulting values were expressed as percent changes compared
with wild-type controls.
In situ hybridization
PCR was used to amplify fragments of the appropriate Hox genes
from mouse adrenal cDNA. All fragments were chosen within an un-
translated sequence that showed no significant homology to othermem-
bers of the Hox family. Corresponding sequences were as follows: for
A9 (accession no. NM 010456), bases 627–999; for B8 (accession no. NM
010461), bases 252–612; and for C8 (accession no. NM 010466), bases
1001–1430. PCR fragments were cloned into pGEM-T Easy (Promega,
Madison, WI) and subsequently sequenced to confirm integrity. The
plasmids were linearized, and nonradioactive sense and antisense ri-
boprobes labeled with digoxigenin were synthesized using in vitro tran-
scription using either T7 or SP6 RNA polymerase as previously de-
scribed (21).
Adrenals from wild-type controls were frozen in isopentane cooled
in dry ice, and 25-m sections were cut using a cryostat. In situ hybrid-
ization was carried out essentially as previously described (21). For the
sense controls, tissue sections were probed with a cocktail of all three
probes mixed together in equal quantities. Detection of the probes was
via an antidigoxigenin antibody (Roche) coupled with the Renaissance
Tyramide Signal Amplification System (NEN Life Science Products,
Boston, MA). The cell nuclei were counterstained with TOTO-3 (Mo-
lecular Probes, Eugene, OR) and the sections analyzed using confocal
microscopy.
Immunoprecipitation
HEK293T cells were transfected with pcDNASf-1 and/or pcDNAP-
bxHA using the calcium phosphate-mediated transfection method. Af-
ter 24 h, cells were harvested by scraping them in a buffer containing 50
mm Tris-HCl, pH 8.0; 150 mm NaCl; 5 mm EDTA; 0.5% Nonidet P-40;
0.1 mm phenylmethylsulfonyl fluoride (22), and 100 mg protein was
incubated at 4 C with 5 l anti-Sf-1 (rabbit polyclonal; Upstate) or
anti-HA (mouse monoclonal, 6E2; Cell Signaling, Danvers, MA). After
12 h, 25 l packed protein A (Invitrogen, Carlsbad, CA) or protein G
agarose beads (Sigma) were added and incubated at 4 C for another
hour. After three consecutive washes with 1 ml IPH buffer, agarose
beads were heated to 95 C in loading buffer containing SDS and mer-
captoethanol for 5 min. Samples were subjected to 10% SDS-PAGE,
transferred to nylonmembrane (Bio-Rad) by semidry technique. Protein
detectionwas conductedusing anti-SF-1 (rabbit polyclonal) and anti-HA
(rabbit polyclonal, Y11; Santa Cruz Biotechnology) and the West Dura
extended duration kit (Pierce, Rockford, IL). Alternatively, instead of
IPH buffer, experiments with immunoprecipitation were carried out in
modified RIPA buffer and 1:1 PBS:modified RIPA buffer obtaining the
same results.
RT-PCR
Individual adrenals from each group were used for RNA extraction
using the QIAGEN (Valencia, CA) RNA mini kit following the instruc-
tions of the manufacturer. cDNA was created using a RT kit (Promega)
and 1.0 g total RNA. Aliquots of the cDNA samples were subjected to
the subsequent PCR, which were performed with primer pairs and
annealing temperatures as given in supplemental Table 1. For detection
of Hox gene products, identical primers as for the generation of the in
situ probes were used. Amplification products were separated on 1%
agarose gel and stained with ethidium bromide.
Real-time PCR
IGF system, Pcna, and Sf-1 in vivo. Quantification of mRNA abundance
was performed by real-time PCR detection using an ABI PRISM 7700
Sequence Detector (PE Biosystems, Weiterstadt, Germany) and Sybr
Green as a double-stranded DNA-specific fluorescent dye. Amplifi-
cation mixes (25 l) contained 2.5 l cDNA solution, 2 Sybr Green
PCRMaster Mix, 12.5 pm of each primer, and 0.25 IU AmpErase uracil
N-glycosylase (PE Biosystems). Amplification primers (Table 1) were
designed using the Primer Express software (PE Biosystems). PCR
was started with 2 min at 50 C for AmpErase activation and 10 min
at 95 C for denaturation. The program continued with 40 cycles of 15
sec at 95 C and 60 sec at 60 C. The amplicons were verified by sequence
determination. Each assay included triplicates of cDNA for the gene
of interest, no-template control and four dilutions of cDNA pooled
from all genetic groups for the gene of interest and for the reference
gene -actin to calculate the corresponding amplification efficiency
(E  10(1/b) 1; b is the regression coefficient). The parameter CT
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(threshold cycle) is defined as the cycle number at which fluorescence
intensity exceeds a fixed threshold. Relative mRNA expression for
each gene of interest (I) was calculated using the formula: (1 
E[I])
CT[I]/(1  E[-actin])
CT[-actin]. Data were analyzed using the
Student’s t test and correlation analysis (Pearson).
In vitro Sf-1-Pbx1 interaction, Pbx1, and Mc2-r in vivo. For these sets of
experiments, real-time PCR was performed using the FastStart DNA
MasterPlus SYBR Green I reaction mix in the LightCycler 1.5 (Roche).
Real-time PCR conditions were preincubation at 95 C for 10 min fol-
lowed by amplification of 40–45 cycles at 95 C for 10 sec, the annealing
temperature (primer dependent as given in Table 1) for 6 sec, and
extension at 72 C, at which the time is calculated by the product length
in base pairs divided by 25 (Roche, Indianapolis, IN). The melting curve
analysis was performed between 65 and 95 C (0.1 C/sec) to determine
the melting temperature of the amplified product and to exclude un-
desired primer dimers. Furthermore, the products were run on a 1%
agarose gel to verify the amplified product. Quantification was adjusted
using the housekeeping gene2-microglobulin. To facilitate overall com-
parison of individual real-time experiments, expression levels of the
particular genes were set as 100% for wild-type animals.
For evaluation of endogenous gene expression after forced overex-
pression of Sf-1 and Pbx1, cells were harvested 48 h after transfection,
and real-time analysis was performed as described.
Reporter gene assays
A 2.7-kb fragment of the murine 5 untranslated region of the Pbx1
gene was PCR cloned using primers 5-PBX1prom-3, TTC CCA CTT
GGC GAA AAG AAA TCA GAG CC, and 3-PBX1prom-3, CCA GAA
CCA ATC TGT CCT TCA AAC TGC CTC, from mouse genomic DNA
using the Expand Long Template PCR System (Roche, Indianapolis, IN).
Cycling conditions and procedure were performed according to the
manufacturer’s protocol. The PCR product was first cloned into pCR2.1
vector using TA cloning kit (Invitrogen, Karlsruhe, Germany) and sub-
sequently subcloned into the pGL2 basic vector (Promega).
In addition, a full-length promoter construct of the ACTH receptor
(Mc2-r) and a construct with three mutated Sf-1-binding sites that have
been described previously (23) as well as an artificial Sf-1-responsive
element consisting of multiple core Sf-1-binding sites from the 21-OH
genes fused to 36 PRL-LUC (kindly provided by Dr. K. Parker) were
used. For stimulation, expression vectors for the full-length murine
Pbx1a and Sf-1 were used, respectively.
Mouse adrenocortical Y1 cells were grown to a density of 100,000 per
24-well plate in Ham’s F-10 medium with 7.5% horse serum and 2.5%
fetal bovine serum and transiently transfected using ExGen 500 (MBI
Fermentas, St. Leon-Rot, Germany) for 5 h according to the manufac-
turer’s instructions with 250-ng expression vectors (if not stated other-
wise) and 500-ng promoter constructs, respectively. Total amount of
transfected DNA was kept constant to 1 g by adding empty pcDNA
expression vector. At 48 h after transfection, cells were harvested and
luciferase activity was measured (Luciferase Reporter Gene Assay;
Roche, Mannheim, Germany). Luciferase values were normalized for
total protein content. Each data point represents at least four indepen-
dent measurements.
Plasma hormone measurements
Plasma corticosterone was measured using a commercially available
RIA (MP Biomedicals, Eschwege, Germany). Plasma ACTH was deter-
mined with an immunoradiometric assay (Immuno Biological Labora-
tories, Hamburg, Germany). All assayswere performed according to the
manufacturers’ protocols. The intra- and interassay coefficients of vari-
ation were less than 10% and less than 7%, respectively, for all assays.
All hormone measurements were performed on six animals per geno-
type on single aliquots due to the small amount of plasma available.
Statistical analysis
All results are expressed as mean  sem. If not stated otherwise, all
statistical comparisons were analyzed by ANOVA and Fisher’s protec-
tive least significant difference test. Statistical significance is defined as
P  0.05 and is indicated by asterisks in the figures.
TABLE 1. Primer sequences and annealing temperatures used for real-time PCR
Amplification product Sequence Nucleotides Annealingtemperature (C)
20-HSD (fwd) GTACAAGCCTGTGTGCAACCA 582–686 60
20-HSD (rev) TCTTCTGGTTGCCTATGGTGC
-actin (fwd) ACCCCAGCCATGTACGTAGC 465–565 60
-actin (rev) CTCTGCCCCAGTGGGTGTG
FGF-15 (fwd) CAGAACTGAGAGCCAGGAGC 1095–1545 62
FGF-15 (rev) CAAAGCCAAAAGGCTGAAAG
IGF-I (fwd) ATGAGTGTTGCTTCCGGAGCT 272–352 60
IGF-I (rev) GGATGTTTTCGTCGGGCGA
IGF-II (fwd) GCATGCTTGCCAAAGAGCTC 450–550 60
IGF-II (rev) TGCCCCCTCGGAGAAGC
IGF-I-R (fwd) CCGCGCCAGTTTTGATG 4026–4098 60
IGF-I-R (rev) TTGCTCTCCCGGAACGGA
IGFBP-2 (fwd) GCGCGGGTACCTGTGAAA 403–482 60
IGFBP-2 (rev) CTACTGCTGGTGAGACTCCCT
IGFBP-3 (fwd) CCTCCGAGTCTAAGCGGGAG 686–786 60
IGFBP-3 (rev) TACACGACTCAGGGTCTCCG
IGFBP-5 (fwd) CTGCCCACCCCAGAGTCAT 575–675 60
IGFBP-5 (rev) GGGAGGTCCTCAAGTTTCGG
MC2-R (fwd) CTGCCACGAGGCTTAAGATAAC 663–1150 58
MC2-R (rev) GCCTGTCAAGCATTAGTGACAA
Pbx1 (fwd) GGGTGCAGGTTCAGACAACT 302–711 58
Pbx1 (rev) CGCACTTCTTGGCTAACTCC
PCNA (fwd) ATCAATGAGGCCTGCTGGG 196–296 60
PCNA (rev) CTTACTCTGCGCTCCGAAGG
SF-1 (fwd) TGCACTGCAGCTGGACCGCCAGGAGTT 1248–1638 58
SF-1 (rev) AGGGCTCCTGGATCCCTAATGCAAGGA
StAR (fwd) GACCTTGAAAGGCTCAGGAAGAAC 7–938 58
StAR (rev) TAGCTGAAGATGGACAGACTTGC
Nucleotide positions are given relative to the start codon of the respective open reading frame. fwd, Forward, 5–3; rev, reverse, 3–5. For
further details, see text.
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Results
Pbx1, Hox genes, and Sf-1 are constitutively expressed in
the adrenal cortex of the adult mouse
Expression of the transcription factors Pbx1 and Sf-1 was
detectable in the adrenal cortex on the mRNA level (Fig. 2A)
as well as by immunohistochemistry (Pbx1, Fig. 2B; Sf-1, Fig.
2C). Moreover, major Pbx1 binding partners such as Hox A9,
B8, and C8, which are essential mediators of Pbx1 action (2,
24–26), were also present in the adrenal cortex by means of
in situ hybridization and RT-PCR analysis (Fig. 2D). These
results provided the rationale for investigating the effects of
Pbx1 haploinsufficiency on the adrenal cortex.
Pbx1 haploinsufficient mice are characterized by lower
adrenal weights with smaller x-zone but adrenocortical
hypertrophy
Pbx1/ animals displayed smaller adrenals (Fig. 3B) re-
sulting in a significantly lower adrenal weight (4.4 0.4 mg)
in comparison with wild-type controls (7.5  0.3 mg, P 
0.0001; Fig. 3, A and C). Despite the lower adrenal weight,
morphometric analyses demonstrated hypertrophy of the
zona fasciculata as indicated by a lower cell number per
high-power field in Pbx1/mice (63.0 3.3%; Fig. 3, E and
F) than in wild-type animals (89.3  8.3%, P  0.014; Fig. 3,
D and F).
In contrast, morphological studies based on the x-zone-
specific expression pattern of 20HSD (Fig. 3, G and H)
suggested a decrease in the size of the x-zone in nulliparous
female mice in the context of Pbx1 haploinsufficiency (Fig.
3H) in comparison with wild-type controls (Fig. 3G). These
observational findings could be verified by morphometric
analysis (ratio x-zone area/whole adrenal cortex area,
100.0  6.3 vs. 57.3  13.9%, P  0.05; Fig. 3I).
Pbx1 haploinsufficiency is associated with lower adrenal
cellular proliferation, decreased compensatory adrenal
growth, and changes of expression in the IGF system
Because the observed lower adrenal weight in Pbx1/
animals could have been explained by a proliferation defect,
detailed expression analysis of the proliferationmarker Pcna
was performed. Indeed, Pbx1 haploinsufficient mice dis-
played a marked reduction in adrenal expression levels of
Pcna, which was observed in real-time PCR (52.3  12.5 vs.
100 7.6%, P 0.01; Fig. 4A),Western blot analysis (Fig. 4B),
and immunohistochemistry (Fig. 4C).
To further substantiate these findings on adrenocortical
proliferation under baseline conditions, we used the well-
defined growth paradigm of compensatory adrenal growth
after unilateral adrenalectomy (27). In accordance with the
results from female animals, adrenal weights in male mice at
baseline were significantly lower in Pbx1/ mice in com-
parison with wild-type controls (1.6  0.1 vs. 2.1  0.1 mg,
P  0.002). Moreover, unilateral adrenalectomy resulted in
a blunted compensatory growth of the contralateral adrenal
in Pbx1/ animals (1.7  0.1 mg, P  0.65 vs. baseline) in
contrast to wild-typemice that showed the expected increase
in adrenal weight (2.7  0.1 mg, P  0.001 vs. baseline; Fig.
4D).
Because the IGF system is a major determinant of adre-
nocortical growth in adrenal physiology and tumorigenesis,
this system was investigated thoroughly by real-time anal-
ysis. Although IGF-I and IGF-II expression levels were not
different between the two genotypes, IGF-I receptor was
significantly down-regulated (46  6 vs. 100  10%, P 
0.007). Furthermore, IGF-binding protein 2 (IGFBP-2) was
up-regulated about 10-fold (1033.0  408.5 vs. 100  8.3%,
P  0.04), whereas IGFBP-3 and IGFBP-5 expression levels
remained unaltered by Pbx1 haploinsufficiency (Fig. 4E). In
accordance with the lower IGF-I receptor mRNA expression
levels, adrenals from Pbx1/ also displayed lower IGF-I
receptor protein levels by means of Western blot analysis
(67.3  4.1 vs. 100.0  7.8%; P  0.03; Fig. 4E, inset).
Taken together, these findings indicate that a full comple-
ment of Pbx1 is indispensable for proper growth and pro-
liferation of the adrenal cortex. In addition, the transcrip-
tional modulation of the intraadrenal IGF system associated
with Pbx1 haploinsufficiency might contribute to the ob-
served adrenal growth defect.
FIG. 2. Adrenal expression pattern of Pbx1, Sf-1, and Hox genes.
Expression of Pbx1 (A and B) and Sf-1 (A and C) in the adult adrenal
cortex was detected by RT-PCR and immunohistochemistry. More-
over, expression pattern of HoxA9, HoxB8, and HoxC8 was investi-
gated by in situ hybridization and RT-PCR, indicating expression of
the Hox genes in all zones of the murine adrenal cortex (D). In con-
trast, no specific staining was evident using amixture of sense probes
of each individual Hox gene (D, sense).
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Pbx1 haploinsufficient mice have a blunted steroid response
after stimulation
On a functional level, baseline corticosterone levels were
similar in Pbx1/ (18.8 6.2 ng/ml) and wild-type (16.7
4.7 ng/ml, P 0.8) animals. In contrast, corticosterone stim-
ulation was significantly blunted in Pbx1/ mice after
ACTH administration (184.4  57.6 ng/ml vs. wild-type
358.8  28.3 ng/ml, P  0.03), whereas no statistical differ-
ence could be observed after restrained stress experiments
(375.0  36.3 ng/ml vs. wild-type 495.9  51.2 ng/ml, P 
0.14; Fig. 5). Accordingly, basal ACTH levels were similar
between the two groups (259.0  25.2 pg/ml vs. wild-type
296.0  37.0 pg/ml, P  0.60) but significantly higher in
Pbx1/mice after restrained stress (1177.5 57.8 pg/ml vs.
wild-type 797.3 112.8 pg/ml, P 0.02; Fig. 5). Collectively,
these data correspond with a compensated primary adrenal
insufficiency in Pbx1 haploinsufficient mice.
Pbx1 and Sf-1 induce promoter activation of the ACTH
receptor without evidence for direct physical interaction
Consistent with the hormonal data suggesting a decreased
responsiveness of the adrenal cortex to ACTH expression
levels of the ACTH receptor [melanocortin receptor (Mc2-r)]
were significantly lower in Pbx1/ animals (77.7 7.9%) in
comparison with wild-type controls (100  2.8%, P  0.02;
Fig. 6A). Therefore, we further evaluated possible direct in-
teraction of Pbx1 on the transcriptional regulation of the
Mc2-r. In addition to the three well-characterized Sf-1-bind-
ing sites within the Mc2-r promoter (28), sequence analysis
predicted two potential Pbx1/Hox and two potential Pbx1/
Meis binding sites, displaying the consensus TGATNNAT
(29) and TGACAG (30) at positions 63 to 56, 326 to
319, 686 to 681, and 915 to 910 bp, respectively.
Accordingly, promoter studies using a full-lengthMc2-r pro-
moter construct revealed a significant increase in promoter
activation by Pbx1 (342.0 81.2% vs. pcDNA100 4.7%,P
0.007) which was of similar magnitude as that induced by
Sf-1 (520.8  121.3 vs. 100  4.7%, P  0.002). In addition,
overexpression of Pbx1 together with Sf-1 resulted in an
additional significant increase in Mc2-r promoter activity
over Sf-1 alone (1627.4 408.2 vs. 520.8 121.3%, P 0.001;
Fig. 6B).
Using the full-length Mc2-r promoter with mutated SF-1-
binding sites at positions35,98, and209, no significant
FIG. 3. Adrenal phenotype of female Pbx1 heterozygous animals. Female Pbx1/ mice were characterized by smaller adrenals (B) with
significant lower adrenal weights (C) in comparison with wild-type controls (A), whereas lower cell number per high-power field within the zona
fasciculata (F) indicated cellular hypertrophy in Pbx1/mice (E) comparedwithwild-type animals (D). Expression pattern of the x-zone-specific
marker 20hsd (G and H) gave evidence for a smaller x-zone in Pbx1/mice (H) in comparison with wild-type controls (H) that was quantified
by x-zone morphometry verifying smaller x-zone area in Pbx1 heterozygous animals (I). Bars for low- and high-power magnification represent
500 and 100 m, respectively. D, Definitive zone; M, medulla; X, x-zone.
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Sf-1 responsewas detectable (133.4 3.7 vs. 100 11.0%, P
0.14), whereas Pbx1-dependent effects on the promoter ac-
tivity remained intact either alone (169.1  17.2 vs. 100 
11.0%, P 0.01) or in combination with SF-1 (232.9 20.6 vs.
100  11.0%, P  0.001; Fig. 6C).
Using an artificial Sf-1 promoter construct, which con-
sisted of multiple isolated Sf-1-binding sites, only Sf-1-
dependent effects on promoter activation were evident (Sf-1
alone, 433.9  13.8 vs. 100  8.2%, P  0.001; Pbx1 plus Sf-1,
370.4  16.5 vs. 100  8.2%, P  0.001), whereas Pbx1 was
not able to significantly increase promoter activity over base-
line (94.6  8.8 vs. 100  8.2%, P  0.76) or over Sf-1-
dependent activation alone (370.4  16.5 vs. 433.9  13.8%,
P  0.07), respectively (Fig. 6D).
Collectively, these data demonstrate that Pbx1 and Sf-1
have additive effects on Mc2-r promoter activity. Moreover,
Sf-1 seems not to be required for Pbx1 to evoke its activating
effects on the Mc2-r promoter. Conversely, Pbx1 fails to in-
crease Sf-1-dependent effects on promoter activation in the
absence of Pbx1-binding sites.
Because a functional interaction between Pbx1 and Sf-1
could require direct protein-protein binding, we performed
immunoprecipitation experiments under various conditions
(Fig. 6E and data not shown). However, overexpression of
Sf-1was not able to coprecipitate Pbx1, suggesting that direct
interaction between the two transcription factors seems not
to play a major role for the observed functional effects on
promoter activation.
FIG. 4. Pbx1 haploinsufficiency results in an adrenal proliferation defect.
Adrenal expressionof theproliferationmarkerPcnawas reducedbymeans
of RT-PCR analysis (A), immunoblotting (B), and immunohistochemistry
(C) in the context of Pbx1 haploinsufficiency. In addition, compensatory
adrenal growth after unilateral adrenalectomy was blunted in male
Pbx1/mice in comparison with wild-type controls (D). Expression anal-
ysis of members of the IGF system by real-time PCR (E) revealed signifi-
cantly decreased adrenal expression of IGF-I receptor (Igf1-r) and marked
up-regulation of IGFBP-2 mRNA levels in Pbx1/ animals. Accordingly,
IGF-Ireceptorprotein levelsweresignificantlydiminished inadrenals from
inPbx1/mice(E, inset).Bars forimmunohistochemistryrepresent50m.
ADX, Unilateral adrenalectomy.
FIG. 5. Pbx1 haploinsufficiency is accompanied by compensated pri-
mary adrenal insufficiency. Although baseline ACTH and corticoste-
rone levels were not different betweenwild-type animals and Pbx1/
mice (A and B), ACTH stimulation resulted in a blunted adrenal
corticosterone response in Pbx1/mice in comparisonwithwild-type
controls (A). In contrast, stress-induced ACTH levels were signifi-
cantly elevated in Pbx1/mice indicating compensatory increase in
ACTH secretion (B).
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Pbx1 does not affect Sf-1 expression levels in adrenocortical
tumor cell lines in vitro and in adult adrenal glands in vivo
Expression of Fgf15, which represents a direct down-
stream target of Pbx1 action (31), was up-regulated by over-
expression of Pbx1 in Y1 cells in a dose-dependent manner
(247.4  29.8% for 1000 ng Pbx1 vs. 100  1.7% for pcDNA,
P  0.03; Fig. 7A). In contrast, endogenous Sf-1 expression
levels remained unchanged (119.4  2.4% for 1000 ng Pbx1
vs. 100  6.6%, P  0.12; Fig. 7C) under the same experi-
mental conditions. Concomitantly, Sf-1 expression levels in
adrenal glands of wild-type and heterozygous Pbx1 mice
were assessed by real-time PCR and Western blot analysis.
In accordance with the in vitro data, Sf-1 expression in adult
adrenals onmRNA (115.3 17.0 vs. 100 6.6%,P 0.39; Fig.
7D) or protein level (102.5  7.3 vs. 100  14.5%, P  0.90;
Fig. 7E) was not significantly different in Pbx1/ mice in
comparison with wild-type controls.
Sf-1 induces Pbx1 promoter activation in vitro and in vivo
Upon overexpression of Sf-1 in Y1 cells, the direct Sf-1
target gene mStAR (170.5  18.6 vs. 100  9.4%, P  0.001;
Fig. 7E) aswell as endogenous Pbx1 (165.65 19.4% vs. 100
11.6%, P  0.01; Fig. 7F) were significantly up-regulated in
the Sf-1-transfected cells, indicating Sf-1-dependent activa-
tion of endogenous Pbx1 transcription.
In accordance with these in vitro findings in Y1 cells, se-
quence analysis of the Pbx1 promoter predicted four poten-
tial Sf-1-binding sites represented by a CAAGG consensus
sequence (positions 11 to 15 and 2465 to 2454) and
AGGTCA consensus sequence (32) (positions 2465 to
2460 and 2312 to 2307). Notably, four consensus bind-
ing sites for Pbx1were also evidentwithin the Pbx1 promoter
region (1942 to 1933, 982 to 975, 639 to 632, and
535 to542) by sequence analysis. Functional significance
of these findings was verified by Pbx1 promoter stimulation
studies. In accordance with the sequence analysis, overex-
pression of Sf-1 resulted in a dose-dependent increase in
Pbx1 promoter activation (125 ng Sf-1, 157.7  6.9%, P 
0.017; 250 ng Sf-1, 188.4 8.9%,P 0.014; 500 ng Sf-1, 272.2
17.0%, P  0.001 vs. pcDNA, 100  4.7%; Fig. 7G). Further-
more, Pbx1 promoter activity was also significantly induced
by Pbx1 overexpression (331.1  24.0 vs. 100  4.7%, P 
0.001; Fig. 7G). In vivo, adrenal glands of Sf-1 heterozygous
animals showed significantly lower Pbx1 levels on the
mRNA level (43.3 15.3 vs. 100 12.7%, P 0.047; Fig. 7H).
Taken together, these data are in agreement with the concept
of an Sf-1-dependent promoter activation of Pbx1.
FIG. 6. Pbx1 and Sf-1 independently up-regulate
expression of the ACTH receptor (Mc2-r). In vivo,
adrenalMc2-r expressionwas significantly lower in
Pbx1/mice in comparisonwithwild-type controls
(A). Using a full-length Mc2-r promoter construct,
both Pbx1 and Sf-1 led to a significant increase in
promoter activity (B). Moreover, Pbx1 and Sf-1 in
combination resulted in an additional significant
increase over promoter activity induced by Sf-1
alone (B). In contrast, a Mc2-r promoter construct
with mutated Sf-1-binding sites could only be stim-
ulated by Pbx1, whereas no further activation was
evident by Sf-1 (C). Conversely, using an artificial
Sf-1-responsive promoter construct, Pbx1 did not
increase promoter activity (D). However, no direct
protein-protein interaction between Pbx1 and Sf-1
could be established by immunoprecipitation ex-
periments (E). S and P in schematic promoter con-
structs denote Sf-1-binding sites and consensus
Pbx1-binding sites, respectively.
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Discussion
Regulation andmaintenance of adrenocortical growth and
steroidogenesis is dependent upon extraadrenal peptide hor-
mones as well as the presence of intraadrenal transcription
factors. The adrenal phenotype in Pbx1 haploinsufficient
animalswith lower adrenalweight, lower basal proliferation,
and lack of compensatory adrenal growth as well as blunted
steroid output upon stimulation demonstrates the require-
ment of a full complement of Pbx1 for proper adrenocortical
growth and function.Notably, these defects in adrenocortical
cellular proliferation and steroidogenesis recapitulate the
phenotype as observed in Sf-1 heterozygous knockout mice
(20, 33).
The observed decrease in the cell number per high-power
field in Pbx1/ mice indicating cellular hypertrophy of the
zona fasciculata clearly does not explain the concomitant re-
FIG. 7. Transcriptional interdependence between Pbx1 and Sf-1. Although overexpression of Pbx1 in Y1 cells resulted in a significant up-
regulation of the Pbx1 downstream target Fgf15 in a dose-dependent manner (A), endogenous Sf-1 levels were not affected by Pbx1 overex-
pression (B). Accordingly, Pbx1 haploinsufficiency did not significantly alter adrenal Sf-1 mRNA levels (C) or protein expression (D) in vivo.
In contrast, overexpression of Sf-1 in Y1 cells led to increased mRNA levels of the Sf-1-dependent downstream target StAR (E) as well as
endogenous Pbx1 (F). Moreover, Pbx1 promoter activity was significantly increased by Sf-1 in a dose-dependent manner as well as by Pbx1 itself
(G). Likewise, in vivo adrenal expression levels of Pbx1 were significantly decreased in Sf-1 haploinsufficient animals (Sf-1/) compared with
wild-type controls (H).
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duction in adrenal weight. However, similar phenotypic
changes have been demonstrated in Sf-1 haploinsufficientmice
(19, 20, 33) and have been interpreted as the consequence of
latent primary adrenal insufficiency with consecutively ele-
vated levels of ACTH and other proopiomelanocortin-derived
peptides togetherwith intracellular compensatorymechanisms
including up-regulation of the orphan nuclear receptor nerve
growth factor-induced B (NGFI-B) (34). Likewise, although a
smaller x-zone might contribute to the observed decrease in
adrenal weight in virgin female animals, it does not explain the
lower adrenal weight in postpubertal male mice with already
regressed x-zone. As such, cellular hyperplasia of the zona
fasciculata or differences in zonation seem not to be major
determinants of the observed adrenal growth defect.
The adrenal cortex is a dynamic organ with constant cel-
lular replacement from the proposed subcapsular stem cell
zone and inwardmigration of newly differentiated daughter
cells (35, 36). As such, growth and adaptation of the adult
adrenal cortex is dependent upon the proliferative potential
of this stem cell population. Thus, the observed lower levels
of the proliferation marker PCNA as detected by RT-PCR,
Western blot analysis, and immunohistochemistry suggest a
crucial role of Pbx1 for the regulation of adrenocortical stem
cell proliferation. In keeping with these findings, severe ad-
renal hypoplasia has been described in Pbx1/ embryos
(15), which parallels the defects in proliferation of progenitor
cells previously reported in other organ systems (7, 10). The
lack of compensatory growth in Pbx1/ animals resembles
that of Sf-1 heterozygous mice (20) and provides additional
evidence that Pbx1 is indispensable for the maintenance of
the adrenal cortex in the adult animal.
IGF-II is considered one of the most potent growth factors
for the adrenal cortex in the context of both adrenal devel-
opment (37) and adrenal tumorigenesis (38). Genetic studies
on adrenocortical carcinomas have demonstrated a variety of
genetic changes resulting in IGF-II overexpression. There-
fore, we hypothesized that alteration in the local IGF system
might play a role in the observed lower proliferation at
baseline and upon stimulation. Indeed, although no changes
in expression levels of IGF-I or IGF-II are evident in adrenals
from Pbx1/ animals, adrenal IGF-I receptor expression is
significantly down-regulated, whereas IGFBP-2 expression
levels are considerably higher in Pbx1/ mice. These de-
scriptive data on expression levels in a complex and dynamic
in vivo system have to be interpreted with caution. However,
because the main effects of IGF-I in the adrenal cortex are
mediated by the IGF-I receptor and IGFBP-2 has been dem-
onstrated tomodulate IGF-I-dependent action on the adrenal
cortex (39), both changes in expression levels could contrib-
ute to the evident proliferation defect.
Development of the adrenal cortex and functional main-
tenance in the adult organism is dependent upon an intact
hypothalamus-pituitary-adrenal axis, in that a lack of pitu-
itary proopiomelanocortin causes severe adrenal hypoplasia
(40). The Mc2-r is a central part of the hypothalamus-pitu-
itary-adrenal axis by mediating the adrenal steroid output in
response to pituitaryACTH (41).As such, the observed lower
adrenal expression levels of the Mc2-r are in line with the
blunted adrenal responsiveness to ACTH in vivo in Pbx1
haploinsufficient animals.
In addition to its well described binding sites for Sf-1 (23,
28), theMc2-r promoter contains four binding sites for Pbx1/
Hox and Pbx1/Meis heterodimers, respectively. Interest-
ingly, the proximal promoter fragment from position12 to
109 contains one Pbx1/Hox-binding site that is flanked by
two Sf-1-binding sites in close proximity. This promoter se-
quence is highly conserved between Homo sapiens and Mus
musculus, displaying about 80% sequence similarity. Because
these findings gave indirect evidence for the functional rel-
evance of these transcription factors forMc2-r regulation, we
used the Mc2-r promoter as a model for Pbx1- and Sf-1-
dependent promoter activation. In fact, Pbx1 results in an
increase in baseline as well as Sf-1-stimulated promoter ac-
tivity of the Mc2-r promoter, establishing Mc2-r as a direct
target of Pbx1-dependent action. Although the proximity of
binding sites for the two transcription factors implies direct
protein-protein interaction of Pbx1 and Sf-1, immunopre-
cipitation provides no evidence for direct physical binding of
the two transcription factors under the chosen experimental
conditions. In addition, promoter experiments using aMc2-r
construct with site-directedmutated Sf-1-binding sites argue
for Pbx1-induced promoter activation independent from
Sf-1. Conversely, an artificial promoter construct consisting
of multiple Sf-1-binding sites is not activated by Pbx1. Taken
together, these findings suggest a parallel albeit independent
promoter activation of the Mc2-r promoter by Pbx1 and Sf-1.
However, Pbx1 has been demonstrated to penetrate inactive
chromatin structures to facilitate the access of other tran-
scription factors to appropriate promoter regions (3). In this
regard, we cannot exclude the possibility that in vivo Pbx1
could also facilitate Sf-1 binding to DNA, thus boosting its
transcriptional activity.
Because Sf-1 expression in adrenals from Pbx1-deficient
embryos has been reported to be reduced (15), these findings
indicate a Pbx1-dependent transcriptional activation of Sf-1
and would place Pbx1 before Sf-1 in the temporal expression
of transcription factors during urogenital development. In
fact, in a recently published paper, Zubair and co-workers
(16) provide ample evidence for a Pbx1-dependent initiation
of Sf-1 transcription during early adrenal development that
is further maintained by a positive auto-feedback loop by
Sf-1 itself at later developmental stages. These findings in-
dicate that Pbx1-dependent transcriptional activation of Sf-1
is dependent on the physiological and cellular context. In
fact, as shown herein, Sf-1 expression levels in adrenals from
Pbx1 haploinsufficient animals are not diminished in com-
parison with wild-type controls, and overexpression of Pbx1
in adrenocortical Y1 cells does not affect endogenous Sf-1
expression. Although we cannot exclude the possibility that
one remaining allele of Pbx1 is sufficient to drive full ex-
pression of Sf-1 in adrenals of Pbx1/ animals, it is also
possible that transcriptional regulation of Sf-1 in the adult
organism differs from that during early organogenesis.
Conversely, we present evidence suggesting that Sf-1 in-
duces up-regulation of Pbx1 transcription. First, up-regula-
tion of endogenous Pbx1 can be induced by overexpression
of Sf-1 in adrenocortical Y1 cells. Second, sequence analysis
of the Pbx1 promoter reveals the presence of four Sf-1-bind-
ing sites containing the consensus sequence CAAGG (posi-
tions 11 to 15 and 2465 to 2454) and AGGTCA (po-
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sitions 2465 to 2460 and 2312 to 2307) (32). Third,
cloning of the 5 region of the Pbx1 gene and subsequent
luciferase experiments demonstrate promoter activation of
the Pbx1 promoter fragment by Sf-1 in a dose-dependent
manner. Fourth, adrenal Pbx1 levels are down-regulated in
Sf-1 haploinsufficient animals. Although differences in the
spatiotemporal expression patterns between Pbx1 and Sf-1
with organ-restricted expression for Sf-1 andwith ubiquitous
and early expression for Pbx1 clearly indicate that Sf-1 is not
mandatory for Pbx1 expression in vivo, down-regulation of
Pbx1 in Sf-1/mice suggests modulation of Pbx1 transcrip-
tion by Sf-1 most likely in concert with other transcription
factors. In keeping with this notion, as we can demonstrate
in promoter studies (data not shown), WT-1 is also able to
induce transcriptional activation of Pbx1, which in itself
might be of functional significance for urogenital organo-
genesis. In addition, overexpression of Pbx1 itself results in
up-regulation of its own promoter, forming a positive feed-
back loop system that might contribute to a more stable
expression of Pbx1 in its target cells. Overall, it is tempting
to speculate that the adrenal phenotype in homozygous and
heterozygous Sf-1 knockout animals might be mediated in
part by effects of Pbx1 down-regulation resulting in the phe-
notypical similarities between Sf-1- and Pbx1-deficient
mouse models.
In conclusion, we demonstrate that Pbx1, in addition to its
involvement in urogenital development and adrenocortical
cell commitment, is also required for the growth mainte-
nance of the adult adrenal gland. Furthermore, we present
data suggesting that the growth defects observed in Pbx1
haploinsufficient mice are mainly caused by a defect in ad-
renal cell proliferation under baseline and stimulated con-
ditions. In accordance with the overall similarity in the phe-
notypes of mouse models with haploinsufficiency for Pbx1
and Sf-1, we provide additional evidence for cooperative
interaction between the two transcription factors relying on
transcriptional regulation of Pbx1 by Sf-1 as well as syner-
gistic up-regulation ofmutual target genes such as theMc2-r.
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